$STX

MOSLEY WILLIAM D sold $690K of STX

MOSLEY WILLIAM D (CEO) sold 760 shares of Seagate Technology Holdings plc (STX) at $907.75 ($0.69M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MOSLEY WILLIAM D
Published Jun 2, 2026, 9:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Neutral
high confidence
Mentioned
$STX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

Because the transaction is pre-arranged, it is generally less informative than unscheduled insider selling tied to new information.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 designation reduces the likelihood of a fundamental repricing catalyst.

03

What to watch

The filing does not reveal motives, and the sale size (760 shares) may be small relative to typical executive holdings.

Relevance 6/10Novelty 3/10Timing: Filed June 2 after the June 1 sale; relevant for monitoring into the next trading session.

Background

SEC Form 4 disclosures report insider trades; a 10b5-1 plan indicates trades were scheduled in advance to reduce timing-based trading concerns.

Company-level read

Ticker impact

$STXNeutralHigh confidence
Context

Seagate CEO William D. Mosley sold 760 shares in an open-market transaction disclosed via SEC Form 4 on June 1.

Expected impact

Limited near-term impact; any reaction is likely muted given the 10b5-1 pre-arranged nature.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, and no new operating/financial catalyst is provided.

Market effects

No direct sector read-through; this is company-specific insider liquidity rather than a sector catalyst.

None indicated.

None indicated.

Counterpoint

Insider selling can be interpreted as diversification rather than bearishness, especially when tied to a pre-arranged 10b5-1 schedule.

Key entities

  • Seagate Technology Holdings plc

    Subject of the insider transaction disclosure; CEO William D. Mosley sold shares under a 10b5-1 plan.

  • MOSLEY WILLIAM D

    CEO/officer/director who executed the open-market sale disclosed on Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.